Navigation Links
Human Pheromone Sciences Announces First Quarter Results
Date:5/14/2009

Current Period Results Impacted by Downturn in Worldwide Beauty Markets

SAN JOSE, Calif., May 14 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or the "Company") today announced results for the first quarter ended March 31, 2009. Net revenues of $165,000 represented a 38% decrease from the revenues of $266,000 in the prior year period, and resulted in a net loss of $181,000 ($0.04 per share) as compared with net loss of $63,000 ($0.02 per share) for the same period of 2008. At March 31, 2009, the Company reflected cash balances of $664,000 compared with $907,000 in cash at December 31, 2008, a $243,000 reduction in the quarter. There was no bank indebtedness at either period.

According to a Company spokesperson, "the revenue and cash declines were in line with the Company's internal forecasts, reflecting the extremely difficult overall adverse economic climate and the significant downturn in the worldwide Fragrance and Beauty Markets. We had anticipated the reduction of revenues on sales to our once largest fragrance and beauty-based company, and, as such, embarked upon a program to expand other potential markets for the use of our patented technology in other consumer product arenas. Some of the shortfall in the basic beauty area was offset by supply and royalty revenues received under our licensing agreement with Schwarzkopf & Henkel in the worldwide hair care and personal product markets. Pheromone purchases by our two primary licensees, increased by 79%, in anticipation of a new product launch in May 2009 by one of these companies. While the selling price of the pheromones is quite low compared to that of prior licensees, our newer agreements provide for royalties on licensee sales of products containing our patented technology. As such, we would anticipate an increase in royalty income in subsequent periods this year."

"Generating additional revenues under new licensing agreements will not only grow our business, but will reduce the effect of erratic purchasing patterns by one major licensee. In addition, while the Company is focusing on reducing expenditures, we continue to invest in maintaining our current patents and seeking such protection for our newest technology on a worldwide basis," the spokesperson indicated.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                                 Tables follow



                          HUMAN PHEROMONE SCIENCES, INC.

                            Condensed Balance Sheets
                             (Dollars in thousands)

                                          March 31,             December 31,
                                            2009                    2008
                                            ----                    ----
                                         (Unaudited)
    Assets

    Cash and cash equivalents                   $664                    $907
    Accounts receivable                           61                      52
    Inventories, net                              51                      39
    Other current assets                          34                      58
    Property and equipment, net                    2                       2
                                         -----------             -----------
    Total                                       $812                  $1,058
                                         ===========             ===========

    Liabilities and shareholders' deficit

    Accounts payable                             $54                     $19
    Other current liabilities                    103                     131
    Deferred income - current                    270                     297
    Deferred income - non-current                265                     324
    Common stock                              21,056                  21,043
    Accumulated deficit                      (20,936)                (20,756)
                                         -----------             -----------
    Total                                       $812                  $1,058
                                         ===========             ===========



                          HUMAN PHEROMONE SCIENCES, INC.

                        Condensed Statements of Operations
                                   (Unaudited)
                   (Dollars in thousands, except per-share data)

                                            Three months ended March 31,
                                               2009               2008
                                              ------             ------

    Net revenues                                $165               $266
    Cost of goods sold                            65                 81
    Research and development                      25                 14
    Selling, general and administrative          257                244
                                              ------             ------

    Income (loss) from operations               (182)               (73)

    Other income                                   1                 11

    Provision for income taxes                     -                  1
                                              ------             ------

    Net income (loss)                          $(181)              $(63)
                                              ======             ======


    Income (loss) per share, basic            $(0.04)            $(0.02)
                                              ======             ======

    Income (loss) per share, fully diluted    $(0.04)            $(0.02)
                                              ======             ======

    Weighted average common shares
     Outstanding - Basic                       4,152              4,152
                                              ======             ======
    Weighted average common shares
     Outstanding - Fully diluted               4,152              4,152
                                              ======             ======

    Net income (loss) per share is based on the weighted average number of
    common shares and common equivalents outstanding during each period.
    Certain common stock equivalents are excluded when their effect would be
    anti-dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Embryonic Stem Cells Repair Human Heart
2. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
3. Human Papilloma Virus vaccines may decrease chances of oral cancer
4. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
5. MassMutual Promotes Debra Palermino to Senior Vice President of Human Resources
6. Toddler Study Proves Humans Outsmart Apes
7. Human C-reactive protein regulates myeloma tumor cell growth and survival
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. New class of RNA molecules may be important in human cancer
11. The Humana Foundation and Libraries for the Future Launch Health Literacy Pilot in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with ... in an upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and ... butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product research and development ...
(Date:4/29/2016)... ... 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- ... A. Potter -- are proud of the recent release of their 2014 in vitro ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary data ...
(Date:4/29/2016)... Springfield, MO (PRWEB) , ... April 29, 2016 , ... ... and Technology Seminar on May 3 and 4 at the Doubletree by Hilton Hotel ... that is dedicated to marketing and applications technologies for protein ingredients. , At the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is ... of Microsoft Dynamics GP for one their long-term care clients. Working together with ... GP with key clinical management systems, and delivered a fully integrated accounting and ...
(Date:4/29/2016)... ... April 29, 2016 , ... Pro3rd Grunge is a package of ... lower thirds to introduce people, characters, and locations without having to set a single ... textures and many more design components. Simply select a preset and drag it into ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
(Date:4/28/2016)... Net Sales of $1.90 billion represent an increase of 67.8% ... an increase of 1.2% on an adjusted pro forma, constant ... were $0.52 reported, a decrease of 47.5% from the prior ... the prior year period , The Company increases constant ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ...
Breaking Medicine Technology: